CLEAR LABELS Act
- Sponsor
- Rep. McCormick, Richard [R-GA-7]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Apr 14, 2026
Bottom line
This bill aims to enhance transparency in the pharmaceutical supply chain by requiring detailed manufacturer and supply chain information directly on drug labels or via an accessible electronic portal, potentially impacting drug sourcing and consumer awareness.
What it actually does
This bill amends the Federal Food, Drug, and Cosmetic Act to mandate that drug labels for finished products include the name, place of business, and unique facility identifier of the original manufacturer of each active pharmaceutical ingredient (API) and the finished drug product, along with any packer or distributor. It also requires similar information for APIs themselves and provides an exemption from customs country of origin marking requirements for drugs that comply with these new labeling rules.
Proponents argue
Proponents argue that this bill significantly increases transparency in the drug supply chain, allowing consumers, healthcare providers, and regulators to better understand the origin of their medications. This enhanced visibility could help identify potential sources of contamination, improve recall efficiency, and empower consumers to make more informed choices about the drugs they use, ultimately bolstering drug safety and public trust.
Opponents contend
Opponents might contend that these new labeling requirements impose substantial new compliance burdens and costs on pharmaceutical manufacturers, packers, and distributors, which could ultimately be passed on to consumers or lead to supply chain disruptions. They might also argue that existing regulations are sufficient for tracking drug origins and that the proposed changes are overly prescriptive, potentially revealing proprietary supply chain information to competitors.
The bill is very short and straightforward, making it highly accessible for anyone wishing to understand its core provisions quickly.
Section 2, amending 21 U.S.C. 352(b)(1)
Manufacturer, Packer, or Distributor Identification on Finished Drug Product Labels
This provision requires that finished drug products in package form bear a label containing the name, place of business, and unique facility identifier of the manufacturer, packer, or distributor. Alternatively, this information can be provided via a link, barcode, QR code, or other means to access a searchable electronic portal. It also retains the requirement for an accurate statement of quantity.
Supporters argue
Supporters argue this ensures basic accountability for the final product, making it easier to trace responsibility and verify product authenticity.
Critics contend
Critics might argue that existing regulations already provide sufficient traceability and that adding more information to labels or requiring electronic portals adds unnecessary cost and complexity without significant additional benefit.
Tradeoffs
Balances the desire for greater transparency and accountability with the potential for increased regulatory burden on the industry.
Section 2, amending 21 U.S.C. 352(b)(2)
Original Manufacturer Information for Active Pharmaceutical Ingredients (APIs)
This section mandates that active pharmaceutical ingredients (APIs) must have accompanying labels and certificates of analysis that include the name, place of business, and unique facility identifier of the original manufacturer of the API. This aims to provide clear traceability for the core components of drugs.
Section 2, amending 21 U.S.C. 352(b)(3)
Comprehensive Labeling for Finished Drug Products
This provision requires the labeling of finished drug products to include the name, place of business, and unique facility identifier of the original manufacturer of each active pharmaceutical ingredient, the original manufacturer of the finished drug product, and any packer or distributor. This information can also be provided via an electronic portal. If multiple API manufacturers are possible, all must be identified.
Section 2, amending 21 U.S.C. 352(b)(4)
Paper Copy Option for Supply Chain Information
This provision requires manufacturers, packers, or distributors to make the mandated supply chain information available through a package insert or in paper copy to any individual who requests it, even if the primary method of disclosure is electronic.
Section 2, amending 21 U.S.C. 352(b)(6)
FDA Rulemaking Authority and Implementation Timeline
This provision grants the Secretary (of Health and Human Services, via FDA) authority to issue regulations to implement the API and comprehensive finished drug product labeling requirements. It also allows for reasonable variations or alternative placements for labeling, including electronic means. The regulations will take effect no earlier than one year after final publication and apply to drugs manufactured on or after that date.
Section 3, amending 19 U.S.C. 1304
Exemption from Country of Origin Marking for Compliant Drugs
This section amends the Tariff Act of 1930 to exempt finished drug products from standard customs country of origin marking requirements if they are already marked in accordance with the new, more detailed labeling requirements of the Federal Food, Drug, and Cosmetic Act as established by this bill.
Defines "original manufacturer" as the single last establishment to conduct substantial manufacturing activities prior to introduction of the active pharmaceutical ingredient or finished drug product into interstate commerce.
Section 2, amending 21 U.S.C. 352(b)(5)
Why it matters:This is standard legislative practice to define terms within the relevant section of a bill to ensure clarity for implementation, rather than in a separate definitions section.
Case for: Proponents argue this definition provides necessary clarity for enforcement and compliance, ensuring that a specific, identifiable entity can be held accountable as the 'original' source for regulatory purposes.
Case against: Critics might argue that the term 'substantial manufacturing activities' could still be open to interpretation, potentially leading to disputes or loopholes, especially in complex, multi-stage manufacturing processes where different entities contribute significantly.
Estimated impact: This definition directly impacts which entities are designated as 'original manufacturers' and thus bear the primary labeling responsibility under the new rules, affecting compliance strategies across the pharmaceutical supply chain.
Allows manufacturers to use a link, barcode, QR code, or other means to access a searchable electronic portal containing required manufacturer and supply chain information, instead of printing it directly on the physical label.
Section 2, amending 21 U.S.C. 352(b)(1)(A) and 352(b)(3)(A)
Why it matters:This is standard legislative practice to offer alternative compliance methods, providing flexibility to regulated entities while still achieving the policy goal.
Case for: Proponents argue this provides crucial flexibility for manufacturers, allowing them to provide extensive information without cluttering physical labels, and enables dynamic updates to information. It also leverages modern technology for efficiency.
Case against: Critics might argue that relying on electronic portals could create a barrier for individuals without internet access or digital literacy, or that it makes immediate access to critical information less convenient than direct label printing, despite the paper copy provision.
Estimated impact: This option significantly influences the practical implementation and cost for manufacturers, as it allows for digital solutions rather than extensive physical label redesigns, and affects how consumers will access detailed drug origin information.
Specifies that regulations implementing the API and finished drug product labeling requirements shall take effect on a date determined by the Secretary, but not earlier than 1 year after the date of publication of the final regulations.
Section 2, amending 21 U.S.C. 352(b)(6)
Why it matters:This is standard legislative practice for setting implementation timelines for new regulations, ensuring that agencies have time to develop rules and regulated entities have time to comply.
Case for: Proponents argue this provides the pharmaceutical industry with a necessary transition period to adapt their manufacturing, labeling, and supply chain tracking systems to comply with the new requirements, minimizing disruption and ensuring a smoother rollout.
Case against: Some advocates for immediate transparency might argue that a minimum one-year delay after final regulations are published (which itself follows a potentially lengthy rulemaking process) could unduly postpone critical safety and transparency measures.
Estimated impact: This clause determines the earliest possible date for industry compliance and when consumers will begin to see the new labeling information, significantly affecting the pace of the bill's intended impact.